The US Food and Drug Administration (FDA) has granted emergency use authorisation (EUA) for Abbott’s molecular test for coronavirus (Covid-19).
The molecular tests are run on the company’s m2000 RealTime System, a molecular solution with a broad range of tests.
Following the EUA, Abbott is shipping 150,000 RealTime SARS-CoV-2 tests to existing customers in the US.
Abbott chairman and CEO Miles White said: “A global challenge like coronavirus requires the commitment and cooperation of everyone who has the ability to help address it.